NCT02832089已完成3 期
Oral Carvedilol in Escalating Doses in the Acute Treatment of Atrial Fibrillation
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 30
- 主要终点
- reduction in ventricular rate in AF patients
研究概览
简要总结
Oral carvedilol administered in escalating doses in patients with atrial fibrillation among patients with AF with fast ventricular rate.
详细描述
Patients with AF with FVR of any etiology were evaluated and given escalating doses of oral carvedilol in doses - 3.125mg OD, then 3.125 bid, then 6.25mg bid, then 12.5mg bid. The ECG was recorded regularly and analysed for rate reduction or control.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •AF with fast ventricular rate
排除标准
- 未提供
研究组 & 干预措施
active arm
Experimental
single arm study with one group given oral carvedilol.
干预措施: oral carvedilol (Drug)
结局指标
主要结局
reduction in ventricular rate in AF patients
时间窗: 24 hours
reduction in ventricular rate in patients with AF and fast ventricular rate.
次要结局
未报告次要终点
研究者
Ravi Venkatachelam Chitrapu
doctor
Andhra Medical College
相似试验
进行中（未招募）
不适用
Carvedilol for Prevention of Paroxysmal Atrial FibrillationAtrial FibrillationNCT01608893University of Calgary300
已完成
不适用
Carvedilol Versus Metoprolol for the Prevention of Atrial Fibrillation After Off-Pump Coronary Bypass SurgeryCoronary DiseaseAtrial FibrillationNCT00198614Ministry of Health, Labour and Welfare, Japan650
已完成
4 期
Rate Control in Atrial FibrillationRapid Ventricular Response Atrial FibrillationNCT01655303Tehran University of Medical Sciences90
已完成
3 期
RATe Control in Atrial FibrillationAtrial FibrillationNCT00313157Asker & Baerum Hospital80
Unknown
4 期
Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease StudyAtrial FibrillationNCT02642419Japan Cardiovascular Research Foundation2,200